DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 776,229 shares of the medical device company’s stock after selling 29,434 shares during the period. Rhumbline Advisers’ holdings in DexCom were worth $60,367,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of DXCM. Creative Planning raised its position in shares of DexCom by 22.3% in the third quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock worth $3,994,000 after acquiring an additional 10,880 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of DexCom by 1.3% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 40,973 shares of the medical device company’s stock worth $2,747,000 after acquiring an additional 527 shares during the period. Blue Trust Inc. raised its position in shares of DexCom by 101.9% in the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after acquiring an additional 898 shares during the period. Revolve Wealth Partners LLC raised its position in shares of DexCom by 209.6% in the third quarter. Revolve Wealth Partners LLC now owns 6,640 shares of the medical device company’s stock worth $445,000 after acquiring an additional 4,495 shares during the period. Finally, DMC Group LLC raised its position in shares of DexCom by 34.0% during the 3rd quarter. DMC Group LLC now owns 5,882 shares of the medical device company’s stock worth $394,000 after purchasing an additional 1,492 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $89.07 on Monday. The firm has a 50 day simple moving average of $82.44 and a 200-day simple moving average of $75.49. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $34.79 billion, a price-to-earnings ratio of 53.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. On average, analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock worth $3,628,069. 0.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several research analyst reports. Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Leerink Partners reduced their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.